AUROBINDO

PRESS RELEASE

8th June 2011

Aurobindo Pharma receives final approval for Alprazolam Extended-Release Tablets from USFDA

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Alprazolam Extended-Release Tablets 0.5mg, 1mg, 2mg, and 3mg.

Alprazolam Extended-Release Tablets 0.5mg, 1mg, 2mg, and 3mg is the generic equivalent to the reference listed drug Xanax® XR Tablets 0.5mg, 1mg, 2mg, and 3mg of Pharmacia and Upjohn. Alprazolam Extended-Release Tablets are indicated for the treatment of panic disorder, with or without agoraphobia and fall under the Central Nervous System (CNS) therapeutic segment. The product has a market size of approximately US$ 26.5 million for the twelve months ending September 2010 according to IMS and will be launched soon.

Aurobindo now has a total of 137 ANDA approvals (107 Final approvals and 30 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com